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Abstract 
Background: Cutaneous malignant melanoma (CMM) is one of the most common skin cancers worldwide. Limited 
information is available in the current scientific literature on the concordance of genetic alterations between primary 
and metastatic CMM. In the present study, we performed next-generation sequencing (NGS) analysis of the main 
genes participating in melanoma pathogenesis and progression, among paired primary and metastatic lesions of 
CMM patients, with the aim to evaluate levels of discrepancies in mutational patterns.
Methods: Paraffin-embedded tumor tissues of the paired lesions were retrieved from the archives of the institu-
tions participating in the study. NGS was performed using a specific multiple-gene panel constructed by the Italian 
Melanoma Intergroup (IMI) to explore the mutational status of selected regions (343 amplicons; amplicon range: 
125–175 bp; coverage 100%) within the main 25 genes involved in CMM pathogenesis; sequencing was performed 
with the Ion Torrent PGM System.
Results: A discovery cohort encompassing 30 cases, and a validation cohort including eleven Sardinian patients with 
tissue availability from both the primary and metachronous metastatic lesions were identified; the global number of 
analyzed tissue specimens was 90. A total of 829 genetic non-synonymous variants were detected: 101 (12.2%) were 
pathogenic/likely pathogenic, 131 (15.8%) were benign/likely benign, and the remaining 597 (72%) were uncertain/
unknown significance variants. Considering the global cohort, the consistency in pathogenic/pathogenic like muta-
tions was 76%. Consistency for BRAF and NRAS mutations was 95.2% and 85.7% respectively, without statistically 
significant differences between the discovery and validation cohort.
Conclusions: Our study showed a high level of concordance in mutational patterns between primary and metastatic 
CMM, especially when pathogenic mutations in driver genes were considered.
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Background
Cutaneous malignant melanoma (CMM) is one of the 
most common skin cancers worldwide [1]. CMM inci-
dence constantly increases in the last decades, and 
mortality rates rise, especially in white males [2]. CMM 
mortality is higher in advanced stage cases, not suit-
able for complete surgical removal, in which traditional 
chemotherapy is often characterized by poor oncologi-
cal benefits [3]. Consistent improvements in survival in 
this subset of patients were obtained with the introduc-
tion of targeted and immunological therapies in recent 
years. Actually, targeted therapies are performed with 
the combination of BRAF inhibitors (dabrafenib, vemu-
rafenib, encorafenib) and MEK inhibitors (cobimetinib, 
trametinib, binimetinib) in patients with CMM carry-
ing a BRAF mutation (approximately, 50% of the cases), 
MEK inhibitors alone in BRAF wild-type cases with 
NRAS mutations, and KIT inhibitors (imatinib, nilo-
tinib, etc.) in patients with KIT mutated lesions [4]. In 
other words, targeted therapies are based on the knowl-
edge of specific genetic alterations occurring in the 
tumors to treat. Unfortunately, tumors are not static, 
but dynamic entities and their mutational landscape 
continuously changes during their progression from 
premalignant lesions to metastasis, and can also be 
influenced by the therapeutic interventions adopted.
Several studies have been performed in the past to 
evaluate the concordance of BRAF and NRAS muta-
tions between primary tumors and their metastases in 
order to better understand the pathophysiology of the 
metastatic process in CMM, and to respond on spe-
cific clinical issues regarding the quality of mutational 
analysis is tissue from metastases in comparison to that 
performed in the primary tumor [5]. Some of these 
studies showed a good concordance between primary 
tumors and lymph node or visceral metastases, but low 
rates when soft tissue metastatic samples were com-
pared with the primary lesions [6–8]. Nevertheless, 
studies with consistently lower concordance rates, also 
between primary and lymph node or visceral metasta-
ses, have been published [9, 10]. Most of these reports 
regarding BRAF and NRAS used a single conventional 
method for identifying the mutations, and enrolled 
small cohorts, undermining the validity of conclusions, 
and making further investigations necessary. Additional 
studies employing conventional sequencing evaluated 
the concordance of the specific mutations on other 
genes participating in the oncogenic process of CMM, 
like CDKN2A, MITF, EGFR, CCND1, cMET, and cKIT 
and others, evidencing differences in genes selected 
during tumor progression (like CDKN2A, MITF, etc.) 
[11]. Globally, all the studies mentioned elucidated only 
a small frame of the global change of the mutational 
landscape of metastatic CMM, in comparison to the 
origin tumors.
The advent of next-generation sequencing (NGS) tech-
nologies for genetic testing accelerated the efforts to 
identify the whole pattern of mutations involved in the 
CMM pathogenesis [12]. Recent whole exome (WES) 
or genome sequencing (WGS) studies provided pre-
cious details regarding genetic alterations in numerous 
genes included in a wide range of molecular pathways 
and networks in melanomagenesis and thus allowing 
the molecular sub-classification of the several types of 
melanoma [13–17]. Nevertheless, limited information is 
available on the concordance of the genetic alterations 
reported between primary and metastatic melanomas; 
such information is crucial for the comprehension of the 
single roles and the interplay between specific genetic 
events in the metastatic process, as well as for establish-
ing the validity of testing in CMM metastatic tissue for all 
the mutations in genes used in clinical practice for cur-
rent and future targeted therapies. In the present study, 
we performed NGS-based analysis of the main genes 
participating in melanoma pathogenesis and progres-
sion, included in a specific gene-panel designed by the 
Italian Melanoma Intergroup (IMI) on the basis of pre-
vious studies, in paired primary and metastatic lesions 
of patients with CMM, with the aim to evaluate poten-
tial discrepancies in mutational patterns. Although a 
more detailed picture of the pathogenic changes could 
be obtained with larger gene panels or, more extensively, 
WES/WGS screening approaches, the use of a panel con-
taining a limited number of driver genes may be much 
easier to be introduced into the clinical practice.
Materials and methods
Patients
Consecutive Italian patients with a histologically proven 
diagnosis of metastatic CMM from January 2009 to 
December 2017 were retrieved from the archives of the 
southern Italy anatomic pathology institutes participat-
ing in the study, and cases with tissue availability from 
both the primary and at least one metachronous lymph 
node or visceral metastatic lesion were identified. Meta-
static melanomas were considered as metachronous 
when melanoma metastasis was diagnosed after at least 
6 months from the diagnosis of the primary melanoma. 
Patients with soft tissue metastases were excluded 
because of the low concordance in mutational rates in 
comparison with the primary lesions described in older 
studies, as mentioned above [6–8]. Brain metastases 
samples were not available in any case. In addition, using 
the same criteria, a validation cohort of consecutive Sar-
dinian patients with available paired primary and meta-
static CMM samples was identified from the archives of 
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the Anatomic Pathology Unit of the University of Sassari, 
within the same time frame. The demographic, clini-
cal and pathological data of all patients were retrieved 
from clinical records and reports. All the patients gave 
their informed consent for the use of their clinical data 
for the purposes of the study. The study was performed in 
accordance with the principles of the declaration of Hel-
sinki and was approved by the Committee for the Ethics 
of the Research and Bioethics of the National Research 
Council (CNR).
Molecular analysis
For mutation analysis, paraffin-embedded tumor tissues 
of the paired lesions were retrieved from the pathologi-
cal archives of the institutions participating in the study. 
Using light microscopy, tissue sections were selected in 
order to obtain tumor samples with at least 80% neoplas-
tic cells. Genomic DNA was isolated using the GeneRead 
DNA FFPE Kit (Qiagen, Hilden, Germany), following the 
manufacturer´s instructions. NGS was performed using a 
specific multiple-gene panel constructed by the IMI (IMI 
somatic DNA panel), arranged in three primer pools, and 
designed using the Ion AmpliSeq Designer to explore 
the mutational status of selected regions (343 amplicons; 
amplicon range: 125–175 bp; coverage 100%) within the 
25 genes reported as the most frequently mutated in 
CMM specimens by The Cancer Genome Atlas (TGCA) 
and successive NGS-based studies [12, 13]. Figure 1 sum-
marizes the characteristics of the IMI panel. Although 
this is the first time the IMI gene panel is used in a study, 
several genomic DNA samples from FFPE melanoma tis-
sues were blindly analyzed in separate Italian laboratories 
using different NGS platforms in order to achieve full 
validation of the IMI panel for mutation pattern detec-
tion at somatic level (Ghiorzo and Palmieri, manuscript 
in preparation). Barcoded amplicon libraries were gener-
ated from 10 ng template DNA × primer pool and puri-
fied with AMPure beads (Beckman Coulter, Brea, CA, 
USA). Purified DNA was diluted at a final concentration 
of 50 pM, placed into the Ion Chef for emulsion PCR and 
Chip (316 v2BC) loading, and sequenced on the Ion Tor-
rent PGM System (Life Technologies, Waltham, MA, 
USA). Sequencing data were processed with the Ion Tor-
rent platform-specific pipeline software (Torrent Suite, 
V5.2.1; Life Technologies); the Ion Reporter and Integra-
tive Genome Viewer were used for variant annotation 
and reads visualizations, respectively (http://www.broad 
insti tute.org/igv).
Fig. 1 The Italian Melanoma Intergroup (IMI Somatic DNA panel) used for genetic testing including 343 amplicons, size range 125–175 bp, 
coverage 100%, within the main 25 genes involved in the pathogenesis of melanoma
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Coverage of > 300 reads and frequency of mutated 
alleles > 3% for gene amplicon, in order to get a total 
amount of at least 10 mutated alleles for each candidate 
amplicon, were adopted for mutation selection criteria at 
somatic level. In the discovery cohort, a total of 844,153 
reads was achieved for selecting 750 nucleotide variants, 
with an average of 1125 reads per mutated gene ampli-
con (range, 302 to 2000). In the validation cohort, a total 
of 70,576 reads was achieved for selecting 79 nucleotide 
variants, with an average of 893 reads per mutated gene 
amplicon (range, 302 to 2000). Sequence variants were 
classified as pathogenic, likely pathogenic, uncertain 
significance, likely benign, or benign, according to their 
capability to either affect the function of the gene or be 
plausibly linked to the disease. In particular, pathogenic-
ity was assessed through data comparisons using the fol-
lowing sequence databases: the ClinVar archive of reports 
of relationships among medically relevant variants and 
phenotypes (http://www.ncbi.nlm.nih.gov/clinv ar/) and 
the Catalogue Of Somatic Mutations In Cancer (COS-
MIC v88; https ://cance r.sange r.ac.uk/cosmi c).
All mutations in melanoma driver oncogenes (BRAF 
and NRAS) and a fraction of randomly-selected patho-
genic variants with high rates of the mutated alleles in 
the remaining genes were confirmed by Sanger sequenc-
ing of gene-specific amplicons. Briefly, polymerase chain 
reaction (PCR) was performed on 20  ng of genomic 
DNA in a Veriti 96-Well Fast Thermal Cycler (Life Tech-
nologies-ThermoFisher Scientific); all PCR-amplified 
products were directly sequenced using an automated 
fluorescence-cycle sequencer (ABI3130, Life Technolo-
gies). Sequencing analysis was conducted in duplicate 
and in both directions (forward and reverse) for all evalu-
ated samples.
Statistical analysis
Results were expressed as percentages, mean 
(mean ± SD) or median values (median and IQR). Vari-
ables distribution was assessed by the Shapiro–Wilk test. 
Statistical differences were assessed using the unpaired 
Student’s t-test or Mann–Whitney rank sum test, the 
Chi-square test or Fisher’s exact test as appropriate. 
Correlations between clinical and genetic variables 
were assessed by Pearson’s or Spearman’s correlation, as 
appropriate. Statistical analyses were performed using 
MedCalc for Windows, version 15.4 64 bit (MedCalc 
Software, Ostend, Belgium).
Results
Thirty-five national cases with tissue availability from 
both the primary and at least one metachronous lymph 
node or visceral metastatic lesion were identified. Among 
them, five patients were excluded because of the low 
quality of the DNA extracted, and thus, the remaining 
30 were enrolled in the study. Among the 15 Sardinian 
cases identified, eleven patients were enrolled and four 
were excluded because of sample DNA degradation. The 
global number of patients enrolled was 41, and the total 
of tissue samples retrieved 90 (Fig. 2); the primary CMMs 
were 41 and the metastatic lesions 49. Paired primary 
and lymph node metastasis specimens were available in 
31 cases, while paired primary and visceral metastasis 
samples were obtained in 18 cases (nine liver, eight lung, 
and one small intestine metastasis).
The main demographic, clinical and pathological char-
acteristics of the cohorts included in the study are sum-
marized in Table 1; no statistically significant differences 
were found in such characteristics between the discov-
ery and validations groups, with the exception of sex (all 
patients in the validation cohort were males) and the 
number of mitoses in the primary lesions which were sig-
nificantly lower in the validation group.
A total of 829 genetic variants were detected in all the 
90 lesions examined; the incidence of the variants was 
significantly higher in the discovery cohort (750 vari-
ants) in comparison to the validation cohort (79 variants, 
p = 0.001). All the genetic variants detected are included 
in Additional file 1: Table S1. The variants were classified 
as pathogenic/likely pathogenic, benign/likely benign, 
and uncertain/unknown significance variants in accord-
ance with the COSMIC and ClinVar databases as men-
tioned above (Additional file  2: Table  S2); globally, 101 
(12.2%) variants were pathogenic/likely pathogenic, 131 
(15.8%) were benign/likely benign, and the remaining 
597 (72%) were uncertain/unknown significance variants. 
The pathogenic/likely pathogenic variants affected with 
higher frequency the discovery than the validation cohort 
(87 vs. 14), but the difference was not statistically signifi-
cant (p = 0.117). Furthermore, these variants were equally 
distributed between primary and metastatic tumors (49 
vs. 52). Half of the pathogenic/likely pathogenic variants 
involved the BRAF gene (50 variants, 49.5%); other genes 
harboring such variants were NRAS (14 variants, 13.9%), 
TP53 (14 variants, 13.9%), CDKN2A (4 variants, 4%), and 
others (Additional file  2: Table  S2). Conversely, benign/
likely benign variants were most often harbored in the 
TP53 (45 variants, 34.3%), KDR (24 variants, 18.3%), 
PIK3CA (21 variants, 16%), and KIT (20 variants, 15.3%) 
genes.
Considering the global cohort, the consistency in 
pathogenic/pathogenic like mutational patterns between 
primary and metastatic melanomas was 76% (Table  2). 
Consistency was higher between primary lesions and 
lymph node metastasis than between primary tumors 
and visceral metastasis, with the difference being sta-
tistically significant (p = 0.019, Table  2). Furthermore, 
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global primary tumor-metastasis consistency was slightly 
higher in the validation cohort, than in the discovery 
cohort, but the difference was not statistically signifi-
cant (p = 0.708). Concordance was slightly reduced (63%) 
when the functionally known variants (pathogenic/
likely pathogenic + benign/likely benign) were consid-
ered together in the whole cohort, and was significantly 
lower when all the variants were pooled together (24%, 
p = 0.001) (Table  3). We also searched for statistically 
significant differences in pathogenic/likely pathogenic 
mutations concordance by sex, age, and time to metasta-
sis. No sex predilection was found comparing discordant 
with concordant cases (p = 0.722), as well as no statistical 
differences in age [52.5 (IQR 50–67.5) vs. 53 (IQR 46.2–
61.5) years, p = 0.504] and the time to metastasis [13.5 
(IQR 11–40) vs. 18 (0–25.7) months, p = 0.297]. Similar 
results were obtained dividing the patients in age groups 
(less than 50 years vs. 50 years or more, p = 0.466), and 
in groups by the time to metastasis (shorter vs. longer 
than 24 months, which was the mean time to metastasis 
observed, p = 0.726).
We also evaluated the concordance of pathogenic/likely 
pathogenic mutations in the main single genes involved 
in clinical practice for the prescription of targeted ther-
apies (Table  4). Consistency for BRAF mutations was 
95.2% (V600E, V600K, and G469S variants) present in 
both the primary and metastatic tumors. Similarly, con-
sistency for NRAS mutations was 85.7%; one patient had 
an NRAS mutation in the primary tumor and no muta-
tion in the corresponding visceral metastasis examined. 
No significant differences were observed between the 
discovery and the validation cohort.
Discussion
Cutaneous malignant melanoma, like most human can-
cers, is a disease resulting from a dynamic pathogenic 
process characterized by the accumulation of genetic 
alterations in the neoplastic cells, under the pressure of 
several oncogenic stimuli. The main genetic alterations 
necessary for melanomagenesis and early progression, 
have been widely elucidated [18]; less is known about the 
genetic mutational patterns determining and characteriz-
ing regional and distant melanoma metastasis. The latter 
issue is particularly interesting, also for practical reasons, 
in order to determine the clinical validity of mutational 
testing performed in metastatic biopsy specimens.
Fig. 2 Description of the cohorts enrolled in the study
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What can undermine the validity of these tests is the 
occurrence of intratumoral and intertumoral heterogene-
ity. A high number of clones harboring various mutations 
contribute to a great level of intratumor heterogeneity 
of CMM and generate metastases which may originate 
from different subclones. Multiple molecular events on 
a genomic (point mutations, deletions, aberrations, etc.), 
transcriptomic/proteomic (over-, under-expression of 
genes, etc.), and epigenetic (methylation, micro-RNA and 
long non-coding RNA regulation, etc.) level can addition-
ally contribute in further increase such heterogeneity 
[19]. Indeed, all these levels contributed to the molecu-
lar heterogeneity evidenced in The Cancer Genome 
Atlas (TCGA) study, in which across the eleven different 
cancer types included, there were 4473 primary tumor 
samples (104 from melanoma) and 395 tumor metasta-
sis samples (including 369 from melanoma), but only 29 
paired cases from the same patient, and external to the 
TCGA datasets were analyzed [20]. Moreover, the intro-
duction of newly conceived targeted therapies has been 
demonstrated able to impact the mutational landscape of 
melanomas, creating further pressure on clonality, and 
molecular alterations at all the levels mentioned [21]. 
This influences, not only the validity of the diagnostic 
tests but also the effectiveness of the therapeutic strate-
gies adopted and therefore dictates a better knowledge of 
the variations occurring during the course of the disease.
The incidence of the main pathogenic mutations dis-
playing critical roles in melanomagenesis (BRAF: 49.5%, 
NRAS: 13.9%, TP53: 13.9%) in our study was similar to 
Table 1 Demographic, clinical and pathological features of the patients included in the study
Significant p-values are indicated in italics
IPMD interval progression of metastatic disease, LMM lentigo maligna melanoma, NM nodular melanoma, SD standard deviation, SSM superficial spreading melanoma
Characteristics Global cohort  
(41 cases)
Discovery cohort  
(30 cases)
Validation cohort  
(11 cases)
p-value
Male sex, n (%) 28 (68.3) 15 (53.6) 11 (100) 0.003
Age, (mean ± SD), years 55 ± 12.7 53.9 ± 13.2 58 ± 11.1 0.324
IPMD, (mean ± SD), months 24.3 ± 26.4 25.3 ± 29.2 21.1 ± 13.4 0.523
Melanoma type, n (%)
 NM 12 (29.3) 8 (26.7) 4 (36.4) 0.828
 SSM 28 (68.3) 21 (70) 7 (63.6) 0.993
 LMM 1 (2.4) 1 (3.3) 0 (0) 1.000
Melanoma site, n (%)
 A. Primitive
  Head 2 (4.9) 2 (6.7) 0 (0) 1.000
  Neck 3 (7.3) 2 (6.7) 1 (9.1) 1.000
  Trunk 19 (46.3) 13 (43.3) 6 (54.5) 0.776
  Upper limbs 3 (7.3) 2 (6.7) 1 (9.1) 1.000
  Lower limbs 14 (34.1) 11 (36.7) 3 (27.3) 1.000
 B. Metastasis 49 (100) 36 (73.5) 13 (26.5) 0.853
  Lymph nodes 31 (64.6) 23 (63.9) 8 (66.7)
  Visceral 18 (35.4) 13 (36.1) 5 (33.3)
Number of mitosis per smm (mean ± SD) 3.4 ± 3.1 4.1 ± 3.0 1.6 ± 2.5 0.003
Breslow thickness, (mean ± SD) 3.8 ± 2.4 4.0 ± 2.4 3.2 ± 1.4 0.566
Ulceration, n (%) 18 (43.9) 12 (40) 6 (54.5) 0.634
Initial T/N stage, n (%)
 A. T stage
  T1 2 (4.9) 2 (6.7) 0 1.000
  T2 7 (17.1) 5 (16.7) 2 (18.2) 1.000
  T3 19 (46.3) 13 (43.3) 6 (54.5) 0.776
  T4 13 (31.7) 10 (33.3) 3 (27.3) 1.000
 B. N stage
  N0 8 (19.5) 6 (20.0) 2 (18.2) 1.000
  N1 16 (39.0) 11 (36.7) 5 (45.4) 0.723
  N2 13 (31.7) 9 (30.0) 4 (36.4) 1.000
  N3 4 (9.8) 4 (13.3) 0 0.559
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Table 2 Consistency between pathogenic/likely pathogenic mutation patterns in paired primary and metastatic lesions: 
A—all cases, B—discovery cohort, C—validation cohort
Paired tissue types No. of samples Cases with consistent  
mutation pattern (%)
Cases with discrepant 
mutation pattern (%)
A. All cases
 Primary vs. lymph node metastasis 31 27 (87) 4 (13)
 Primary vs. visceral metastasis 18 10 (56) 8 (44)
 Primary vs. metastasis 49 37 (76) 12 (24)
B. Discovery cohort
 Primary vs. lymph node metastasis 23 20 (87) 3 (13)
 Primary vs. visceral metastasis 15 8 (53) 7 (47)
 Primary vs. metastasis 38 28 (74) 10 (26)
C. Validation cohort
 Primary vs. lymph node metastasis 8 7 (87.5) 1 (12.5)
 Primary vs. visceral metastasis 3 2 (67) 1 (33)
 Primary vs. metastasis 11 9 (82) 2 (18)
Table 3 Consistency between variant patterns in paired primary and metastatic lesions: A—classified (pathogenic/likely 
pathogenic and benign/likely benign) variants, B—all variants
Paired tissue types No. of samples Cases with consistent  
mutation pattern (%)
Cases with discrepant 
mutation pattern (%)
A. Pathogenic/likely pathogenic + benign/likely benign variants
 Primary vs. lymph node metastasis 31 23 (74) 8 (26)
 Primary vs. visceral metastasis 18 8 (44) 10 (56)
 Primary vs. metastasis 49 31 (63) 18 (37)
B. All variants
 Primary vs. lymph node metastasis 31 9 (29) 22 (71)
 Primary vs. visceral metastasis 18 3 (17) 15 (83)
 Primary vs. metastasis 49 12 (24) 37 (76)
Table 4 Consistency in BRAF and NRAS pathogenic/likely pathogenic variants in our cohort
Cases with a mutation  
in the primary tumor
Consistent mutation 
pattern with metastasis 
(%)
BRAF mutations
 Primary vs. lymph node metastasis 18 17 (94.4)
 Primary vs. visceral metastasis 3 3 (100)
 Primary vs. metastasis 21 20 (95.2)
 Discovery cohort 17 17 (100)
 Validation cohort 4 3 (75)
NRAS mutations
 Primary vs. lymph node metastasis 3 3 (100)
 Primary vs. visceral metastasis 4 3 (75)
 Primary vs. metastasis 7 6 (85.7)
 Discovery cohort 5 4 (80)
 Validation cohort 2 2 (100)
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that published in previous studies performed with NGS 
techniques, with the exception of KIT mutations. De 
Unamuno Bustos et  al., Reiman et  al., and Siroy et  al. 
sequenced samples from 100, 151 and 699 CMM cases, 
with custom Ampliseq panels or pan-cancer hot spot 
NGS panels [22–24]. In these studies, the frequency 
of BRAF, NRAS, and KIT mutations was respectively 
36–50%, 15–27%, 4–5%; in our study no pathogenic KIT 
variants were detected, while several unknown/uncer-
tain and benign/likely benign were encountered. Simi-
larly, in a previous study performed by the IMI using 
the AmpliSeq Cancer Panel HotSpot V2/CHPv2 on the 
Ion Torrent platform which investigates approximately 
2800 mutations in 50 most common oncogenes and 
tumor suppressor genes, only KIT polymorphisms, but 
no mutations, were detected [25]. In a further study per-
formed with conventional methods in the Italian popu-
lation, including Sardinian patients, KIT amplifications 
were detected in 3.3% of the primary and 5.4% of the 
metastases examined [11].
Previous studies reported that the number of mutations 
in genes involved in the MAPK pathway, including BRAF 
and NRAS, was increased from premalignant lesions to 
melanoma; it was therefore stated that MAPK becomes 
activated at the earliest stage of neoplasia and progres-
sively ramps up as malignant transformation proceeds 
[13, 26]. Nevertheless, this process seems to be completed 
in the early phases of melanomagenesis, because MAPK 
pathway mutations are constantly present in metastatic 
tissues with similar percentages as in primary lesions, with 
BRAF and NRAS mutations as almost mutually exclusive 
genetic events [27]. Shein et al. examined 12 pairs of pri-
mary CMM and the corresponding regional metastases 
and found most of the pathogenic mutations were shared 
between primary and metastatic lesions; other additional 
private mutations were detected, as occurred in our 
cohorts, but there is no evidence that their selection was 
associated with the metastatic spread [26]. In the study 
of Miraflor et  al. performed with an NGS panel consist-
ing of 207 amplicons covering over 20,000 bases across 50 
genes with known cancer associations, a total of 8 patients 
with paired specimens were screened for somatic muta-
tions [28]. Among them, four cases showed the same 
mutations in their metastatic lesions from different sites 
(ATM, NRAS, TP53, BRAF and JAK3 mutations), while 
the remaining four patients harbored different gene muta-
tions at metastatic sites compared to their primary lesions 
or metastasis from different sites (BRAF, CDKN2A, 
PIK3CA, and ATM mutations).
In our previous study, performed with the AmpliSeq 
HotSpot cancer panel, asynchronous (9 cases) and syn-
chronous (16 cases) metastatic lymph nodes and the cor-
responding primary melanoma tissues were sequenced 
and no significant differences in BRAF/NRAS mutation 
rates between primary (19 of 25; 76%) and metastatic (39 
of 50; 78%) lesions were observed, indicating that BRAF/
NRAS mutations may occur early in melanoma develop-
ment, and their incidence may remain quite unvaried 
during melanoma progression [25].
Our current results confirmed the high consistency 
level of pathogenic/likely pathogenic mutations between 
the primary tumors and the lymph node metastasis 
(87%). Concordance rates, were significantly lower when 
the visceral lesions were tested in comparison to lymph 
node metastases. This could raise some concerns, as cur-
rent clinical guidelines recommend to perform muta-
tional analysis on metastatic tissue in patients with 
advanced stage CMM, and if unavailable, to test the pri-
mary lesions [29, 30]. Nevertheless, when the pathogenic 
mutations to compare were restricted to the BRAF and 
NRAS activating variants, the concordance was higher 
irrespective of the metastatic site, confirming that genetic 
analysis can be performed in both types of lesions. The 
decreasing trend of consistency in pathogenic variants 
from primary to regional and then to distant metastasis 
supports the theory of the accumulation of genetic alter-
ations during the linear progression of CMM, on which is 
based the surgical removal of lymph nodes with curative 
intent. Concordance rates do not seem to be influenced 
by sex, age or time to metastasis. The higher muta-
tional discrepancies were observed in previous studies 
in soft tissue and brain metastases [6, 31], and for this 
reason, we decided to exclude these subsets of patients, 
which need specific studies and alternative guideline 
recommendations.
In our study, and in most of the previous studies men-
tioned, high rates of concurrent BRAF (55%) and NRAS 
(20%) mutations were detected [26]. Furthermore, a 
great number of uncertain/unknown genetic variants 
was found. It is hard to predict the pathophysiological 
and clinical impact of these variants, and if they are or 
not passenger alterations which sporadically influence 
specific phases of the metastatic process. The validation 
cohort in our study was from Sardinia and had globally 
a lower incidence of these variants; this may be depend-
ent on the genetic peculiarity of island populations. In 
Sardinia, whose population shows a high level of genetic 
homogeneity due to geographical isolation and strong 
genetic drift, different mutation rates in several driver 
oncogenes were already demonstrated for various types 
of cancer by our group [32, 33], strongly suggesting that 
different “genetic background” may also induce discrep-
ant penetrance and distribution of somatic mutations in 
candidate cancer genes. Overall, most of these genetic 
variants do not display relevant roles in the metastatic 
process, as their absence does not prevent or attenuate it.
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Our study has some limitations, mainly the low num-
ber of cases, the retrospective approach used in select-
ing them, and the lack of data regarding the therapies 
employed for the clinical management of the patients 
during the evolution of the disease. We are aware that a 
larger collection of CMM patients with highly detailed 
clinical information could permit to also make com-
parisons between the concordant or discrepant altera-
tions in driver genes and additional factors involved into 
the disease behavior (i.e. responsiveness or resistance to 
therapies, immune status, etc.). On the other hand, this 
is the first specifically designed study to investigate a tai-
lored CMM panel of genetic alterations in primary and 
lymph node and visceral metastatic lesions, with an NGS 
approach, and in any case, includes the higher number of 
paired primary—metastatic tissues evaluated this way.
Conclusions
Our research showed a high level of concordance in muta-
tional patterns between primary and metastatic CMM. 
Consistency was higher for pathogenic/likely pathogenic 
variants, which involved mainly the BRAF, NRAS and TP53 
genes. Furthermore, consistency was higher between pri-
mary tumors and the corresponding lymph node metastasis, 
rather than visceral metastasis. Nevertheless, consistency 
for the main genes implicated in clinical practice (BRAF and 
NRAS) was extremely high, confirming previous evidence 
suggesting that metastatic or primary tissue can both be 
effectively used for mutational analysis. A high number of 
unknown/uncertain variants were detected in both primary 
and metastatic lesions, and their role remains to be eluci-
dated in future studies (Additional file 3: Table S3).
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